Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed375%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

NCT02508896
completedphase_1

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

NCT02270489
completedphase_1

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease

NCT02267434
withdrawnphase_1

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

NCT02758730

Clinical Trials (4)

Showing 4 of 4 trials
NCT02508896Phase 1

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

Completed
NCT02270489Phase 1

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

Completed
NCT02267434Phase 1

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease

Completed
NCT02758730Phase 1

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4